Home › Transthyretin-Related Hereditary Amyloidosis › Pennsylvania › Philadelphia
Transthyretin-Related Hereditary Amyloidosis clinical trials in Philadelphia, PA
4 studies for Transthyretin-Related Hereditary Amyloidosis are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
RecruitingObservational study
- Research Site, Philadelphia
- Research Site, Philadelphia
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
RecruitingObservational study
- Clinical Trial Site, Philadelphia
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RecruitingPhase 3
- Penn Presbyterian Medical Center, Philadelphia
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
RecruitingPhase 3
- Penn Presbyterian Medical Center, Philadelphia
Transthyretin-Related Hereditary Amyloidosis trials in other cities
- Los Angeles, CA5 studies
- New York City, NY5 studies
- Dallas, TX4 studies
- San Diego, CA4 studies
- Durham, NC4 studies
- Boston, MA4 studies
- Baltimore, MD4 studies
- Portland, OR4 studies
- St. Louis, MO3 studies
- Rochester, MN3 studies
- Houston, TX3 studies
- Richmond, VA3 studies
Other studies in Philadelphia
- Cancer (all types)59 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Prostate Cancer44 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer28 studies
- Depression26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.